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Abstract
Introduction Breast cancers can be classified using whole
genome expression into distinct subtypes that show differences
in prognosis. One of these groups, the basal-like subtype, is
poorly differentiated, highly metastatic, genomically unstable,
and contains specific genetic alterations such as the loss of
tumour protein 53 (TP53). The loss of the retinoblastoma tumour
suppressor encoded by the RB1 locus is a well-characterised
occurrence in many tumour types; however, its role in breast
cancer is less clear with many reports demonstrating a loss of
heterozygosity that does not correlate with a loss of RB1 protein
expression.
Methods We used gene expression analysis for tumour
subtyping and polymorphic markers located at the RB1 locus to
assess the frequency of loss of heterozygosity in 88 primary
human breast carcinomas and their normal tissue genomic DNA
samples.
Results RB1 loss of heterozygosity was observed at an overall
frequency of 39%, with a high frequency in basal-like (72%) and
luminal B (62%) tumours. These tumours also concurrently
showed low expression of RB1 mRNA. p16INK4a was highly
expressed in basal-like tumours, presumably due to a previously
reported feedback loop caused by RB1 loss. An RB1 loss of
heterozygosity signature was developed and shown to be highly
prognostic, and was potentially a predictive marker of response
to neoadjuvant chemotherapy.
Conclusions These results suggest that the functional loss of
RB1 is common in basal-like tumours, which may play a key role
in dictating their aggressive biology and unique therapeutic
responses.
Introduction
The retinoblastoma tumour suppressor gene (RB1) encodes a
nuclear phosphoprotein that plays a central role in regulating
the cell cycle [1]. Inactivation of both alleles of this gene is
involved in the development of retinoblastoma, which is a rare
childhood malignancy. The loss of RB1 is also a well-charac-
terised occurrence in many other human tumour types and it is
probable that the p16INK4a-CDK4/6-RB pathway is disrupted
in most human tumours [2]. RB1 regulates progression
through the G1 to S-phase transition of the cell cycle. In cells
entering the cell cycle, extracellular signals induce the expres-
sion of D-type cyclins, which bind to and activate cyclin-
dependent kinases (CDK4 and CDK6); these complexes in
turn lead to the phosphorylation of RB and its dissociation
from E2F family members that then transcriptionally activate
many genes required for the S phase [1]. The INK4 family of
CDK inhibitors (p16INK4a, p15INK4b, p18INK4c and p19INK4d)
inhibits CDK4 and CDK6, retaining RB in its hypo-phosphor-
ylated E2F-associated state, thereby preventing G1 to S-
phase progression. It has recently been shown that CDK4 and
CDK6 (and CDK2) are dispensable for driving the essential
cell cycle; however, they are required in specialised tissues
and possibly to achieve higher levels of proliferation [3].
ANOVA: analysis of variance; CDK: cyclin dependent kinase; DCIS: ductal carcinoma in situ; ER: oestrogen receptor; GEO: Gene Expression Omni-
bus; HER2: human epidermal growth factor receptor 2; LOH: loss of heterozygosity; PBS: phosphate-buffered saline; PCR: polymerase chain reac-
tion; RB1: retinoblastoma; SAM: Significance Analysis of Microarrays; TP53: tumour protein p53; VNTR: variable number tandem repeat.Breast Cancer Research    Vol 10 No 5    Herschkowitz et al.
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Inactivation of the RB1 gene in breast cancer was originally
shown using a series of cell lines [4]. Subsequently, loss of
heterozygosity (LOH) has been observed in primary tumours,
but does not necessarily correlate with low RB1 protein
expression as assessed by immunohistochemistry [5,6]. LOH
has, however, been shown to correlate with low RB1 mRNA
expression [5]. There are also genetic events upstream of RB1
that may be present in breast tumours, which can negatively
impact RB1 function by promoting its phosphorylation, that
include p16INK4a loss [7] and cyclin D1 amplification/overex-
pression [8].
Breast cancer is a heterogeneous disease, which can be sep-
arated into clinically significant subtypes as defined by molec-
ular profiling [9,10]. In addition to reproducible gene
expression differences between these subtypes, specific
molecular alterations continue to be identified that correlate
with each subtype. Tumours of the basal-like subtype generally
have a high mitotic index, tend to be p53 mutated [11] and
highly express the proliferation signature, which is a gene clus-
ter shown to contain many E2F target genes [12,13]. Here we
report that LOH at the RB1 locus occurs at a high frequency
in human basal-like and luminal B tumours, while occurring
infrequently in luminal A and human epidermal growth factor
receptor 2 (HER2)-enriched tumours. p16INK4a is also highly
expressed both by microarray and by immunohistochemistry in
most of the RB1 LOH basal-like tumours, presumably due to a
feedback caused by RB1 loss. These results further illustrate
the unique biology of each breast cancer subtype.
Materials and methods
Patient samples and breast cancer microarray data sets
All human tumour samples were collected from fresh frozen
primary breast tumours using protocols approved by the Insti-
tutional Review Board and were profiled as described previ-
ously using Agilent (Agilent Technologies, United States) oligo
microarrays [9,14-16]. The primary microarray data for the 232
sample data set is available in the Gene Expression Omnibus
(GEO) [GEO:GSE3165]. The data set containing only
tumours with informative LOH status can be found in GEO
[GEO:GSE10884], with 13 new samples in this study.
DNA isolation and detection of RB1 loss of 
heterozygosity
Patient DNA from lymphocytes, normal breast tissues and
breast tumours was isolated using the DNeasy kit (Qiagen,
Germany). We used two polymorphic markers; a variable
number tandem repeat (VNTR) in intron 20 and D13S153; a
microsatellite marker for RB1 LOH analyses. The primers were
previously published for intron 20 [17]. The primers for
D13S153 [AFM058xd6a, AFM058xd6m] were obtained from
the Genome Data Bank (Johns Hopkins University, Baltimore,
MD) [18]. The PCR products were run on the Agilent Bioana-
lyzer using DNA 1000 kit (Agilent, United States). The patient
was called informative when there were two alleles present in
their normal DNA. LOH was called when there was at least a
50% loss of an allele/band in the tumour for at least one of the
two polymorphic markers.
Statistical analysis
The chi-square test and Fisher-Freeman-Halton exact test
were used to examine correlations between RB1 LOH status,
immunostaining and tumour subtype using SAS 9.1 (Cary,
NC). An analysis of variance (ANOVA) and unpaired Student's
t-test were performed and a box plot graph plotted to compare
RB1 LOH status or immunostaining with gene expression
using web based 'Statistics to Use' [19]. A Significance Anal-
ysis of Microarrays (SAM) was performed to identify genes
that were significantly differentially expressed between
tumours with RB1 LOH-positive tumours compared with LOH-
negative tumours [20]. Expression analysis systemic explorer
was used to identify gene ontology categories overrepre-
sented in the RB LOH gene list compared with the genes
present on the array.
Whole genome RVista was used to determine the known tran-
scription factor binding sites overrepresented in the 1 kb
upstream region in the lists of genes examined compared with
the rest of the RefSeq genes in the whole human genome
[21]. Hypergeometric mean analysis was performed as
described by Chung and colleagues [22]; this comparison
gives the likelihood of finding co-occurrences between these
gene sets by chance. The simulation was performed inde-
pendently for each pair of gene sets analysed.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections (approxi-
mately 5 μm) were processed using standard immunostaining
methods. Following deparaffinisation in xylenes, slides were
rehydrated through a graded series of alcohol and rinsed in
PBS. Endogenous peroxidase activity was blocked with 3%
hydrogen peroxidase. Samples were steamed for antigen
retrieval with 10 mM citrate buffer (pH 6.0) for 30 minutes.
Slides were then incubated for 20 minutes with diluted normal
blocking serum. The sections were incubated for 60 minutes
at room temperature with primary antibody pRb (Visionbiosys-
tems Novocastra, NCL-L-RB-358 clone 13A10, 1:50 dilution)
or p16 (Santa Cruz, H-156, 1:50 dilution). The slides were
incubated for 45 minutes with diluted biotinylated secondary
antibody (1:250 dilution) and 30 minutes with Vectastain Elite
ABC reagent (Vector Laboratories, United States). Sections
were incubated in peroxidase substrate solution for visualisa-
tion. Slides were counterstained with haematoxylin and exam-
ined by light microscopy. Tumour immunoreactivity was
scored as: 0 = negative, 1 = weak positive, 2 = moderate pos-
itive and 3 = strong positive. The evaluation of p16INK4a and
RB1 protein staining was performed by two blinded independ-
ent researchers.Available online http://breast-cancer-research.com/content/10/5/R75
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Results
Basal-like tumours show low expression of the RB1 
transcript
Tumours of the basal-like subtype have been shown in several
studies to have a high mitotic rate and to highly express a pro-
liferation gene signature [11,12]. For this reason, we postu-
lated that there might be a defect in the RB pathway in these
tumours. We first examined the expression levels of the core
components and regulators of the RB pathway in a previously
published microarray data set [9,14] that contained 232
microarrays consisting of 184 primary breast tumour samples
and nine normal breast samples (Figure 1). On average, RB1
was expressed at the lowest levels in basal-like tumours and at
the highest levels in luminal A tumours (Figures 1 and 2a),
while the converse was observed for the average expression
of a previously defined proliferation gene signature [9] (Figure
2b). Tumours of the basal-like subtype also frequently showed
high levels of p16INK4a (Figures 1 and 2c) and E2F1 (Figure 1
and data not shown). Cyclin D1 levels, on the other hand, were
elevated mainly in luminal tumours including noticeably higher
expression in many luminal B tumours (Figures 1 and 2d); in
addition, it was recently reported that there are often high level
gains of the 11q13 locus that includes cyclin D1 in luminal
tumours [23], therefore suggesting that cyclin D1 high expres-
sion can be considered a 'luminal event'. Similar findings con-
cerning RB1 mRNA expression and the basal-like subtype
have also recently been reported suggesting that this is a
reproducible expression feature of basal-like tumours [24].
LOH at the RB1 locus is associated with high 
proliferation rates and tumour subtype
Due to the low expression of RB1 message in basal-like
tumours we decided to examine these breast carcinomas for
LOH at the RB1 locus. We investigated 88 paired primary
human breast carcinomas and normal tissue genomic DNA
samples to assess the frequency of LOH in RB1. We used
two polymorphic markers located at the RB1 locus (13q14); a
variable number tandem repeat (VNTR) in intron 20 and
D13S153, that is a microsatellite marker located within intron
2. There were 67 cases that were informative for at least one
of these two markers (see Figure 3a as an example LOH). In
total, 26 tumours showed RB1 LOH for at least one marker
(26 of 67, 38.8%). This is consistent with the frequency of
RB1 LOH seen in previous studies of breast cancer (26 to
47%) [5,6,25].
Next, using a previously defined proliferation gene signature
[9], we clustered the gene expression data for this signature
using just the 67 LOH informative patients (Figure 3b). This
analysis was able to sort the samples into two groups with the
right most group containing most of the RB1 LOH positive
Figure 1
The expression of retinoblastoma pathway members varies across breast cancer intrinsic subtypes The expression of retinoblastoma pathway members varies across breast cancer intrinsic subtypes. Two-hundred and thirty-two human sam-
ples are ordered by subtype according to the five-class single sample predictor from Hu and colleagues [9]. Samples are coloured according to their 
subtype: red = basal-like, dark blue = luminal A, light blue = luminal B, pink = human epidermal growth factor receptor 2 (HER2)-enriched and green 
= normal breast-like. (a) proliferation gene cluster. (b) Retinoblastoma (RB)-pathway genes which are present on the array and passed data quality 
filtering criteria of showing a signal intensity of more than 30 units in both channels.Breast Cancer Research    Vol 10 No 5    Herschkowitz et al.
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tumours (21 of 27, 77.8%). The left most group contained 29
of 40 (72.5%) of the RB1 LOH-normal tumours. It is important
to note, however, that many of the LOH positive tumours that
did cluster in the left group were located on the outer nodes
and still showed higher expression of the proliferation markers
than the tumours in the centre. Overall, an ANOVA showed
that RB1 LOH was highly correlated with the high expression
of the proliferation gene cluster (p = 0.0001) (Figure 3c).
Figure 2
The expression of RB1, p16INK4a and cyclin D1 varies across the breast cancer intrinsic subtypes The expression of RB1, p16INK4a and cyclin D1 varies across the breast cancer intrinsic subtypes. Box plot comparisons of (a) Retinoblastoma 
(RB) 1, (b) proliferation signature, (c) p16INK4a and (d) cyclin D1 mRNA expression relative to the five intrinsic subtypes as defined by the five-class 
centroid predictor.Available online http://breast-cancer-research.com/content/10/5/R75
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We next classified the tumours that were assayed for RB1
LOH analysis according to intrinsic subtype using the five-
class single sample predictor [9]. The frequency of RB1 LOH
varied by molecular subtype (p = 0.0002) (Table 1). The low-
est LOH frequencies were observed in the luminal A (3 of 20,
15%) and normal-like (0 of 7, 0%) subtypes, while the HER2-
enriched subtype had a frequency near the breast cancer aver-
age (3 of 9, 33.3%). The highest frequency of RB1 LOH was
observed in tumours of the basal-like (13 of 18, 72.2%) and
luminal B subtypes (8 of 13, 61.5%), both of which are known
to be highly proliferative tumour subtypes [9-11].
Figure 3
Retinoblastoma (RB) 1 loss of heterozygosity (LOH) is associated with high proliferation Retinoblastoma (RB) 1 loss of heterozygosity (LOH) is associated with high proliferation. (a) An example of LOH detected in a breast tumour 
sample at RB1 intron 20. The arrows point to the missing allele with A7-N being DNA from normal tissue and A7-T is tumour DNA from the same 
patient. (b) Two-way unsupervised hierarchical clustering of breast tumour samples with informative RB1 LOH status (LOH + = blue, LOH - = yel-
low) using the proliferation gene cluster. (c) Box plot comparison of the average proliferation cluster expression to RB1 LOH status.Breast Cancer Research    Vol 10 No 5    Herschkowitz et al.
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RB1 and p16INK4a immunostaining in breast carcinomas
RB1 is expressed ubiquitously in mammary epithelial cells and
typically shows a nuclear staining pattern in normal human
breast tissue (Figure 4a). RB1 immunostaining was statisti-
cally correlated with RB1 message levels (p = 0.0081) but, as
has been described before, RB1 protein expression did not
correlate with RB1 LOH (p = 0.5) [6]; however, a trend for low
expression of RB1 message to occur with RB1 LOH was
observed (p = 0.11). RB1 protein expression also tended to
be low in basal-like tumours (Figure 4b and Table 1), but this
relationship was only near statistical significance (p = 0.064).
High p16INK4a staining (3+), which is a hallmark of lost RB1
function [26,27], was seen in 32 of 119 tumours assayed and
often included both nuclear and cytoplasmic staining (Figure
4c). p16INK4a immunostaining was statistically correlated with
p16INK4a message levels (p = 0.013), especially when high
staining was observed (data not shown). p16INK4a immunos-
taining was also associated with intrinsic tumour subtype (p =
1.41E-05) with 22 of 33 (66.7%) of basal-like tumours show-
ing 3+ staining (Figure 4c, Table 1). The correlation between
RB1 LOH status and p16INK4a expression levels was statisti-
cally significant (p = 0.01) (Figure 4d, Table 2). In addition,
p16INK4a was similarly highly expressed in transgenic murine
mammary tumours with loss of RB function driven by SV40
large T-antigen or T121 (Additional File 1) [14]. When consid-
ered together, these data suggest that RB1 LOH in basal-like
tumours cause a loss of RB1 protein function, which the cells
attempt to compensate for by increasing p16INK4a gene and
protein expression levels.
RB1 LOH gene expression signature
To determine if there was a gene expression signature related
to RB1 LOH, a two-class SAM [20] was performed of RB1
LOH positive tumours vs. LOH-normal tumours. In total there
were 452 genes that varied with RB1 LOH status with a false
discovery rate of 0.94%, as compared with 11 genes identi-
fied at a false discovery rate of 16.7% when a similar analysis
was performed using RB immunostaining data (0 vs. 1, 2 and
3). Of these genes, 423 were highly expressed in tumours with
RB1 LOH and an analysis of the gene ontologies associated
with this gene set showed that cell cycle, cell division, DNA
metabolism, spindle organisation and biogenesis, and
response to DNA damage were the top biological processes
discovered when using Bonferroni-corrected scores. Interest-
ingly, E2F1, E2F3 and E2F5 were present on this supervised
gene list and highly expressed in tumours with RB1 LOH. Also
present in this list was RB1CC1, a regulator of RB1 expres-
sion that has been shown to contain truncating mutations in
breast cancers [28]. We used whole genome RVista to calcu-
Table 1
Subtype specificity of RB1 LOH and RB1 and p16INK4a immunohistochemistry
Basal-like HER2-enriched Luminal A Luminal B Normal-like Total
RB1 LOH
LOH positive 13 (48.2) 3 (11.1) 3 (11.1) 8 (29.6) 0 (0) 27
LOH negative 5 (12.5) 6 (15.0) 17 (42.5) 5 (12.5) 7 (17.5) 40
Total 18 9 20 13 7 67 p = 2.26E-04
RB IHC
0 6 (42.9) 2 (14.3) 3 (21.4) 3 (21.4) 0 (0) 14
1+ 13 (29.6) 5 (11.4) 14 (31.8) 4 (9.1) 8 (18.2) 44
2+ 5 (12.8) 6 (15.4) 14 (35.9) 6 (15.4) 8 (20.5) 39
3+ 7 (35.0) 2 (10.0) 4 (20.0) 7 (35.0) 0 (0) 20
Total 31 15 35 20 16 117 p = 0.0644
p16 IHC
0 2 (8.0) 4 (16.0) 8 (32.0) 6 (24.0) 5 (20.0) 25
1+ 5 (15.2) 3 (9.1) 15 (45.5) 5 (15.2) 5 (15.2) 33
2+ 4 (13.8) 4 (13.8) 9 (31.0) 6 (20.7) 6 (20.7) 29
3+ 22 (68.8) 4 (12.5) 3 (9.4) 3 (9.4) 0 (0) 32
Total 33 15 35 20 16 119 p = 1.41E-05
0 = negative, 1+ = weak positive, 2+ = moderate positive, 3+ = strong positive. P-values determined by Fisher's exact test.
HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry; LOH = loss of heterozygosity; RB1 = retinoblastoma.Available online http://breast-cancer-research.com/content/10/5/R75
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late which transcription factor binding sites might be present
within the 1000 bp upstream regions of these genes [21] and
determined that the top three transcription factor binding sites
with p < 0.005 were E2F4:DP1, E2F1:DP1:RB and
E2F4:DP2, showing that a majority of these genes are likely to
be E2F-regulated; other statistically significant transcription
factor binding sites were HIF1:ARHN. Only 29 genes were
significantly negatively/downregulated from the RB1 LOH
SAM analysis, and there were no significant gene ontology
categories enriched in this list.
RB1 LOH gene expression signature correlates with 
signatures of proliferation and RB-loss
Recently, an RB-loss gene expression signature was derived
using mouse fibroblasts with either acute or chronic knockout
of RB1 using conventional knockout as well as Cre-Lox tech-
nology [29]. As might be expected, this RB-loss signature was
Figure 4
High p16INK4a mRNA and protein levels are associated with retinoblastoma (RB) 1 loss of heterozygosity (LOH) High p16INK4a mRNA and protein levels are associated with retinoblastoma (RB) 1 loss of heterozygosity (LOH). (a) RB1 staining of normal 
breast tissue, (b) RB1 LOH+ basal-like tumour lacking RB1 staining, and (c) the same RB1 LOH+ basal-like tumour showing staining for p16INK4a 
both nuclear and cytoplasmic.(d) Box plot comparison showing high p16INK4a mRNA expression in RB1 LOH + breast tumours.Breast Cancer Research    Vol 10 No 5    Herschkowitz et al.
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highly expressed in basal-like tumours (Additional File 2). This
RB-loss signature significantly overlapped with the prolifera-
tion signature (29 of 139 genes of the RB-loss signature are
contained in the 140 gene human proliferation signature used
here, hypergeometric mean p < 0.001), thus serving as further
evidence that the proliferation signature contains many RB1-
E2F regulated genes. There was statistically significant over-
lap among all three RB-pathway signatures studied here (ie,
RB-LOH, RB-loss and proliferation) as determined by hyper-
geometric mean analysis p < 0.001, and thus all three signa-
tures are probably tracking a common biology that is RB1-E2F
dependent. There were 20 genes that overlapped between all
three gene lists (Figure 5), which included cell cycle-related
genes including the spindle assembly checkpoint proteins
BUB1 and MAD2, and many commonly used chemotherapeu-
tic drug targets including TOP2A (doxorubicin, etoposide),
thymidylate synthetase (5-FU), ribonucleotide reductase M2
(hydroxyurea) and CDC2 (flavopiridol, staurosporine).
All four of these RB-pathway associated lists (RB-LOH, RB-
loss, proliferation signature and the 20 common genes) were
highly predictive of breast cancer patient outcomes when
using a two-class or three-class, average value rank order
expression cutoff and when tested on the NKI295 patient data
set (Figure 6, shown using RB-LOH list and data not shown
for the other three lists that give very similar results) [30], and
on a previously described 251 patient data set (data not
shown) [31]. It should be noted, however, that several groups
have independently identified different gene lists that contain
a large number of so-called proliferation/RB-pathway genes
[13,32-35] and it was expected that the RB-LOH signature
would be a strong prognostic profile.
The RB-pathway associated signatures were predictive of
poor prognosis in breast cancers. But are they predictive of
response to therapy? To answer this question, we determined
if the RB-LOH signature correlated with pathological com-
plete response in a well-annotated data set of neoadjuvant
chemotherapy-treated patients [36]. The study by Hess and
colleagues included 133 patients with stage I to III breast can-
cer that were treated with preoperative weekly paclitaxel fol-
lowed by fluorouracil-doxorubicin-cyclophosphamide
chemotherapy. High expression of each of the four RB-path-
way signatures was associated with pathological complete
response in the breast and regional lymph nodes (Additional
File 3). Thus, high expression of the RB-LOH and proliferation
signatures is associated with a good response to neoadjuvant
chemotherapy in breast cancers.
Table 2
Comparison of p16INK4a immunohistochemistry and RB1 LOH status
p 1 6  I H C  01 +2 +3 + T o t a l
RB1 LOH
LOH- 9 (23.7) 11 (29.0) 11 (29.0) 7 (18.4) 38
LOH+ 1 (3.9) 8 (30.8) 5 (19.2) 12 (46.2) 26
10 19 16 19 64 p = 0.0369
0 = negative, 1+ = weak positive, 2+ = moderate positive, 3+ = strong positive. P-values determined by Chi-square test.
IHC = immunohistochemistry; LOH = loss of heterozygosity; RB1 = retinoblastoma.
Figure 5
Venn diagram showing the overlap between the retinoblastoma (RB) 1 loss of heterozygosity (LOH), proliferation, and RB1-loss gene lists Venn diagram showing the overlap between the retinoblastoma (RB) 1 loss of heterozygosity (LOH), proliferation, and RB1-loss gene lists.Available online http://breast-cancer-research.com/content/10/5/R75
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Discussion
Our understanding of breast cancer biology has been
improved by the identification of genomically defined tumour
subtypes. These subtypes are defined by distinct gene expres-
sion patterns, molecular changes and potentially distinct
developmental cell types of origin adding up to observed dif-
ferences in outcome and responses to therapy. In this report,
we show that the frequency of RB1 LOH varied significantly
according to 'intrinsic' subtype. RB1 LOH occurs at a fre-
quency of 72.2% in basal-like breast tumours and 61.5% in
luminal B tumours, both of which are observed in retinoblasto-
mas in the frequency range of 60 to 75% [37-40]. RB1 protein
staining as assessed by immunohistochemistry, however, did
not correlate with RB1 LOH in our study (as has been
reported before); however, a SAM analysis supervised by RB1
LOH robustly identified many E2F genes, and E2F-regulated
target genes, while the RB1 protein-guided SAM analysis did
not. This suggests that RB1 LOH is a better biomarker of RB-
pathway function than immunohistochemistry staining for total
RB1 protein.
Additional support for the functional loss of RB1 in basal-like
tumours comes from the correlation with high p16INK4a mes-
sage and protein expression. The inverse relationship between
p16INK4a and RB1 expression in breast cancers has been pre-
viously reported [41,42]; however, this relationship and its
association with basal-like tumours is new in this report.
Another intriguing link between p16INK4a and basal-like cells
comes from studies on human mammary epithelial cells, which
have been shown to resemble the basal-like subtype by gene
expression analysis [43,44]. It has been shown that in order for
human mammary epithelial cells to proliferate in vitro in culture
for an extended period they must overcome an RB-mediated
stress associated senescence barrier (stasis), which usually
involves spontaneously losing p16INK4a  expression by pro-
moter methylation [45]. The gene expression changes associ-
Figure 6
Retinoblastoma (RB) 1 loss of heterozygosity (LOH) gene list is highly predictive of breast cancer patient outcome Retinoblastoma (RB) 1 loss of heterozygosity (LOH) gene list is highly predictive of breast cancer patient outcome. Kaplan-Meier survival 
curves showing overall survival (OS) or relapse-free survival (RFS) by dividing the patients in thirds (a, c) or in halves (b, d) using the rank order aver-
age expression values of the RB-LOH signature using the NKI295 breast cancer data set.Breast Cancer Research    Vol 10 No 5    Herschkowitz et al.
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ated with this in vitro transition are similar to those we
previously reported to occur with RB1 LOH [46].
In basal-like tumours in vivo, however, the exact opposite
seems to occur in that the RB-pathway barrier appears to be
RB1 functional loss with a concomitant feedback loop that
induces p16INK4a  gene and protein expression. The link
between high p16INK4a expression being caused by RB1 loss
is known; RB1 recruits Polycomb repression complexes to the
p16INK4a locus, which silence p16INK4a transcription [47]. It is
also well-known that cell cycle inhibition by p16INK4a is RB-
dependent [48] and, therefore, these RB1-deficient breast
tumours would be expected to be refractory to the high levels
of p16INK4a. This explains their high proliferation rates in the
presence of high levels of p16INK4a. High p16INK4a expression
has reproducibly been shown to be associated with poor
prognosis [41,49-51] and in a recent study by Grupka and col-
leagues, p16INK4a staining of sentinel lymph nodes was predic-
tive in determining the presence of non-sentinel node
metastases [52]. Gauthier and colleagues have recently
shown that in ductal carcinoma in situ (DCIS) lesions, high
p16INK4a together with low Ki-67 (proliferation) appears to not
promote tumour progression, while high p16INK4a and high Ki-
67 lead to subsequent tumours [24]. Lastly, it has been dem-
onstrated that the deletion of RB1 in the murine mammary
gland is capable of initiating tumourigenesis and that many of
these resulting tumours have basal-like features (E. Zacksen-
haus, personal communication). In total, these data strongly
argue that the RB-pathway lesion that occurs in most basal-
like tumours is RB1 loss, possibly with a compensatory activa-
tion of p16INK4a.
Basal-like tumours also highly express a recently published
RB-loss gene expression signature [29,32], which we have
shown to have significant similarity to a previously defined pro-
liferation signature and our newly described RB1 LOH signa-
ture. Lastly, the p16INK4a expression seen in DCIS by Gauthier
and colleagues, and the elevated Ki-67 index seen in basal-like
DCIS lesions, suggests that RB1 loss may be an early event
for this tumour type [53].
Similar to basal-like tumours, luminal B tumours also showed
a high frequency (61.5%) of RB1 LOH in our study, but this
was not associated with induction of p16INK4a. The differential
effect of RB1 loss on p16INK4a expression in luminal B versus
basal-like tumour cells implicates other transcription factors in
addition to pRb-E2F in the regulation of this CDK inhibitor in
luminal tumours. In the recent study by Bosco and colleagues,
luminal tumour-derived cell lines were shown to be more pro-
liferative and resistant to hormone therapy after knockdown of
RB1 [32], both of which are signatures of luminal B tumours
[9-11]. The RB-loss signature was shown to be predictive of
outcome in a data set containing only oestrogen receptor pos-
itive (ER+) breast tumours treated with tamoxifen mono-
therapy. Therefore, the loss of RB1 function may also play a
substantial role in the increased proliferation, possible resist-
ance to hormonal therapies and poor prognosis that is seen in
luminal B tumours. In addition, the knockdown of RB1 in
established breast cancer cell lines has recently been shown
to increase sensitivity to a variety of DNA-damaging therapeu-
tic agents [32,54]. While these experiments were performed
with ER+ tumour cell lines, it does open the possibility that the
RB1-defect in basal-like tumours plays a role in their increased
chemosensitivity compared with most luminal tumours
[55,56]. This is supported by our findings of increased neoad-
juvant response in patients expressing high levels of the four
different RB1-proliferation associated signatures.
The presence of LOH is typically thought to indicate that a
mutated allele is present on the other chromosome and that
the LOH makes the cell homozygous or hemizygous for the
mutated allele. There is little published evidence to suggest
that dramatic structural changes aside from LOH are occur-
ring at the RB1 locus in breast tumours. There are a few
reports of alterations in RB1 in breast cancer with two reports
showing structural changes as assessed by Southern blotting
in 7% and 19% of primary tumours [57,58], and no published
reports to our knowledge of point mutations. Interestingly, a
study by Kallioniemi and colleagues looking at RB1 loss in clin-
ical breast cancer samples by fluorescent in situ hybridisation
showed that most of the cells within these tumours contained
two copies of the RB1 gene even when they showed LOH by
restriction fragment length polymorphism at the RB1 locus
[59]. When these studies are considered with the data pre-
sented here, they suggest a complex scenario where one allele
is lost by LOH and the remaining allele/residual protein is com-
promised by an as yet to be identified mechanism(s) that
potentially varies between tumour subtype, and potentially var-
ies even within basal-like tumours. For example, some basal-
like tumours with LOH show complete loss of RB protein,
while others show expression and both types show high pro-
liferation. As opposed to breast cancer, there is a great deal
known about the mechanisms of RB1 loss in retinoblastoma
[60-62]. As in retinoblastoma, it is clear that a combination of
techniques will need to be applied in order to identify the pre-
cise mechanisms of RB1 inactivation in breast cancer.
Conclusion
We have shown that RB1 LOH is a frequent occurrence in
basal-like and luminal B breast tumours and is associated with
deregulation of E2F-regulated genes. Deregulation of the RB-
pathway in cell lines has shown that it may be an important
determinant of response to therapy [32]. Moreover, we have
demonstrated that RB1 loss signatures can be used to predict
neoadjuvant chemotherapy response. Therefore, RB1 function
may be an important biomarker for informing treatment
decisions.Available online http://breast-cancer-research.com/content/10/5/R75
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